CZJ@nihcu.bitnet (05/01/89)
Attached is the Table of Contents and items of interest from the
NIH Guide to Grants and Contracts for 04/28/88.
Jim Cassatt
++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++
Vol. 18, No. 15, April 28, 1989
NOTICES
CHANGE IN THE NUMBERS OF COPIES OF APPLICATIONS TO BE
SUBMITTED FOR AIDS EXPEDITED REVIEW ........................(84/103)......... 1
National Institutes of Health
Alcohol, Drug Abuse, and Mental Health Administration
Index: NATIONAL INSTITUTES OF HEALTH
ALCOHOL, DRUG ABUSE, AND MENTAL HEALTH ADMINISTRATION
HEALTH AND SAFETY GUIDELINES FOR GRANTEES AND CONTRACTORS ..(106/220)........ 1
National Institutes of Health
Alcohol, Drug Abuse, and Mental Health Administration
Index: NATIONAL INSTITUTES OF HEALTH
ALCOHOL, DRUG ABUSE, AND MENTAL HEALTH ADMINISTRATION
REVISED GUIDELINES FOR CORE GRANTS .........................(223/258)........ 2
National Eye Institute
Index: EYE
REVISED GUIDELINES FOR CLINICAL VISION RESEARCH DEVELOPMENT AWARD ........... 3
National Eye Institute (261/291)
Index: EYE
IMPLEMENTATION OF EXPANDED AUTHORITIES FOR GRANTEE ORGANIZATIONS ............ 3
Alcohol, Drug Abuse, and Mental Health Administration (294/351)
Index: ALCOHOL, DRUG ABUSE, MENTAL HEALTH
DATED ANNOUNCEMENTS (RFPs AND RFAs)
COORDINATING CENTER FOR AN ASSESSMENT OF THE EFFICACY OF MINOCYCLINE
IN THE TREATMENT OF RHEUMATOID ARTHRITIS (RFP) .............(357/388)........ 4
National Institute of Arthritis and Musculoskeletal and Skin Diseases
Index: ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES
CLINICAL CENTERS FOR AN ASSESSMENT OF THE EFFICACY OF MINOCYCLINE
IN THE TREATMENT OF RHEUMATOID ARTHRITIS (RFP) .............(401/433)........ 5
National Institute of Arthritis and Musculoskeletal and Skin Diseases
Index: ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES
CULTURED NEURON PROBE (RFP) ................................(436/469)........ 5
National Institute of Neurological Disorders and Stroke
Index: NEUROLOGICAL DISORDERS, STROKE
A FACILITY FOR ANIMAL MODELS FOR VIRAL HEPATITIS EXPERIMENTS (RFP) .......... 6
National Institute of Allergy and Infectious Diseases (481/526)
Index: ALLERGY, INFECTIOUS DISEASES
OPERATE CAENORHABDITIS GENETIC CENTER (RFP) ................(529/555)........ 6
Division of Research Resources
Index: RESEARCH RESOURCES
PRESOLICITATION: COLLABORATIVE STUDIES FOR METHODOLOGIC RESEARCH FOR
MULTI-SITE EPIDEMIOLOGIC SURVEYS OF MENTAL DISORDERS IN CHILD AND
ADOLESCENT POPULATIONS (RFA) ...............................(561/662)........ 7
National Institute of Mental Health
Index: MENTAL HEALTH
AIDS AND ITS BEHAVIORAL CAUSES: CHILDREN'S KNOWLEDGE AND EMOTIONS (RFA) .... 8
National Institute of Child Health and Human Development (665/853)
National Institute of Mental Health (1124/1615)
National Institute on Drug Abuse
Index: CHILD HEALTH, HUMAN DEVELOPMENT, MENTAL HEALTH, DRUG ABUSE
DEVELOPING AND IMPROVING INSTITUTIONAL ANIMAL RESOURCES (RFA) ..(856/951)....10
Division of Research Resources (1618/2190)
Index: RESEARCH RESOURCES
ONGOING PROGRAM ANNOUNCEMENTS
EPIZOOTIOLOGY AND TRANSMISSION OF LYME BORRELIOSIS .............(964/1107)...12
National Institute of Allergy and Infectious Diseases
Index: ALLERGY, INFECTIOUS DISEASES
NOTICES
CHANGE IN THE NUMBERS OF COPIES OF APPLICATIONS TO BE
SUBMITTED FOR AIDS EXPEDITED REVIEW
P.T. 34; K.W. 1014002, 1014006
National Institutes of Health
Alcohol, Drug Abuse, and Mental Health Administration
The number of copies of applications required for investigator-initiated AIDS
research project grant (R01) or First Independent Research Support and
Transition (FIRST) award (R29) applications for expedited review has been
changed. Beginning with the May 2, 1989, receipt date, applicants to NIH and
ADAMHA will be required to submit the ORIGINAL APPLICATION PLUS 24 LEGIBLE
COPIES instead of the presently required 32 copies. The number of copies of
appendix materials remains at 6. This announcement supercedes the earlier
notice published in the NIH Guide for Grants and Contracts, Vol. 17, No. 13,
page 1, April 8, 1988. Applicants for other mechanisms of AIDS research,
development, and training support should refer to the earlier notices from the
NIH Guide (Vol. 17, No. 9, March 11, 1988) for the correct numbers of copies
to be submitted and other relevant information.
HEALTH AND SAFETY GUIDELINES FOR GRANTEES AND CONTRACTORS
P.T. 34; K.W. 1014002, 0725010, 0725020
National Institutes of Health
Alcohol, Drug Abuse, and Mental Health
Administration
This notice is a republication, with minor modifications, of a November 1988
issuance on this subject. It is being reissued to emphasize its continuing
importance.
Organizations receiving grant or contract awards are responsible for
protecting their personnel from hazardous conditions. The Government is not
legally liable for accidents, illnesses, or claims arising out of research
performed under its awards, but the National Institutes of Health (NIH) and
the Alcohol, Drug Abuse, and Mental Health Administration (ADAMHA) are
nonetheless aware that a variety of hazards threaten the safety and health of
both laboratory and clinical research personnel. Accordingly, the guidelines
that follow are designed to (1) identify potential hazards, (2) advise awardee
organizations and investigators of certain standards that should be considered
in order to address particular health and/or safety concerns, and (3)
emphasize that concerns about potentially hazardous conditions could result in
grant or contract funding delays until those concerns have been resolved to
the satisfaction of the awarding component.
1. Sources of potential danger to research personnel include the following
classes of hazard:
a. Biohazards (e.g., Human Immunodeficiency Virus, HIV; other infectious
agents; oncogenic viruses).
b. Chemical hazards (e.g., carcinogens; chemotherapeutic agents; other toxic
chemicals; flammable or explosive materials).
c. Radioactive materials.
2. The following guidelines and standards contain information designed to
assist grantees and contractors in providing a safe work environment for
research personnel. Therefore, depending upon the particular safety hazard at
issue, grantees and contractors are expected to consult these standards.
a. Biosafety in Microbiological and Biomedical Laboratories, U.S. Department
of Health and Human Services, Centers for Disease Control and the National
Institutes of Health. HHS Publication No. (CDC) 88-8395.
b. Recommendations for Prevention of HIV Transmission in Health-Care Settings.
Morbidity and Mortality Report, August 21, 1987, Vol. 35, No. 2S.
c. Update: Universal Precautions for Prevention of Transmission of Human
Immunodeficiency Virus, Hepatitis B Virus, and Other Bloodborne Pathogens in
Health-Care Settings. Morbidity and Mortality Weekly Report, June 24, 1988,
Vol. 37, No. 24.
Vol. 18, No. 15, April 28, 1989 - Page 1
d. Agent Summary Statement for Human Immunodeficiency Viruses (HIV); Included
are HTLV-III, LAV, HIV-1, and HIV-2. Morbidity and Mortality Weekly Report,
April 1, 1988, Vol. 37, No. 24.
e. Recommendations for the Safe Handling of Parenteral Antineoplastic Drugs,
NIH Publication No. 83-2621.
f. NIH Guidelines for the Laboratory Use of Chemical Carcinogens, NIH
Publication NO. 81-2385.
g. Guidelines for Research Involving Recombinant DNA Molecules (49 FR 46266 or
latest revision) and Administrative Practices Supplement.
h. Procedures for the Domestic Handling and Transport of Diagnostic Specimens
and Etiologic Agents, National Committee for Clinical Laboratory Standards,
July 17, 1985, Vol. 5, No. 1.
i. Standards issued pursuant to the National Occupational Safety and Health
Act of 1970 (29 CFR 1910).
j. Standards issued pursuant to the Atomic Energy Act of 1954 (42 USC 2021).
3. Grant applications and contract proposals posing special hazards typically
are identified during the initial review process, but such concerns can
formally be expressed by agency staff or consultants at any time prior to
award. Regardless of the timing of the described concern, grant or contract
funding could be delayed until the matter has been resolved to the
satisfaction of the awarding component.
Special hazards that are identified after an award is made may lead to
suspension of work under the grant or contract pending corrective action by
the awardee. (See 45 CFR 74, Subpart M, concerning grant suspension and 48
CFR 12.5 concerning contract "stop work" orders.)
4. The materials identified in section 2 (a-h) of this notice may be obtained
as follows.
ITEMS a-f: Division of Safety
Office of Research Services
National Institutes of Health
Building, 31, Room 1C02
Bethesda, Maryland 20892
ITEM g: Office of Recombinant DNA Activities
Office of Science Policy and Legislation
National Institutes of Health
Building 31, Room 4B11
Bethesda, Maryland 20892
ITEM h: National Committee for Clinical Laboratory Standards
771 East Lancaster Avenue
Villanova, Pennsylvania 19085
5. Grantee and contractor organizations are not required to submit documented
assurance of their specific attention to the guidelines and standards
identified in section 2 of this notice. However, where dictated by the
circumstances, grantees and contractors should be able to provide evidence
that pertinent health and safety standards have been considered and, where
necessary, have been put in practice. Such evidence may be requested by
appropriate NIH and ADAMHA staff; for example, during a site visit.
REVISED GUIDELINES FOR CORE GRANTS
P.T. 34; K.W. l002046, 07l0030, 07l5l00
National Eye Institute
The National Eye Institute (NEI) has recently revised its application
guidelines for Core Grants for Vision Research (P30). The objectives of the
NEI Core Grant Program are: (l) to enhance an institution's environment and
capability for conducting vision research; (2) to facilitate collaborative
studies of the visual system and its disorders; and (3) to attract scientists
of diverse disciplines to research on the visual system.
To be eligible for Core Grants, institutions must have at least four
NEI-supported investigators, each with at least two years of committed support
remaining on a regular research grant (R0l), FIRST award (R29), or MERIT award
Vol. 18, No. 15, April 28, 1989 - Page 2
(R37) at the time of submission of the application. The NEI currently
provides up to $750,000 (direct costs) over a 5-year period in support of a
Core Grant. An exception to this limit may be made for applications
requesting a Biostatistics Module. Applications that specifically include
such a module may request up to $l,050,000 (direct costs) over a 5-year
period. The purpose of a Biostatistics Module would be the development of
staff and other resources needed to enhance programs of clinical vision
research through the application of epidemiologic and biostatistical
methodology to clinical problems. The NEI has one receipt date for Core Grant
applications: June l of each year. Copies of the new guidelines may be
A FACILITY FOR ANIMAL MODELS FOR VIRAL HEPATITIS EXPERIMENTS
RFP AVAILABLE: RFP-NIH-NIAID-OSD-90-18
P.T. 34; K.W. 1002002, 1002045, 0715125, 0755020
National Institute of Allergy and Infectious Diseases
The Intramural Research Program, Office of the Scientific Director of the
National Institute of Allergy and Infectious Diseases, has a requirement to
house and maintain non-human primates and woodchucks for use in viral
hepatitis experiments. Respondents must have facilities capable of housing
approximately 85 non-human primates at all times (up to 25 infant and juvenile
chimpanzees, and 60 marmosets or monkeys). Additionally, up to 25 other small
animals (primarily woodchucks, but occasionally rabbits and guinea pigs) will
be held. It is required that such facilities have the capacity to move air
through isolation units at a rate of 12-15 air changes per hour. The facility
must have a back-up generator to immediately compensate for any power failures
that may occur. In addition, the facilities proposed by the offeror must
include a waste disposal system capable of sterilizing all waste material
prior to release into available sewage systems. Animals, caging, and
isolation units will be provided by the Government.
Any contract awarded will be subject to DHHS regulations regarding the use of
animal subjects in research.
One contract may be awarded as a result of this solicitation. It is expected
that the contract will have a five-year period of performance.
The issuance of the RFP will be on or about April 28, 1989, and proposals will
be due by the close of business on June 12, 1989. Any responsible offeror may
submit a proposal which will be considered by the Government.
Requests for the RFP should be directed to:
Mr. Thomas C. Porter, Contracting Officer
Contract Management Branch
National Institute of Allergy and Infectious Diseases
National Institutes of Health
Westwood Building, Room 707
Bethesda, Maryland 20892
To receive copies of the RFP please provide this office with two
self-addressed mailing labels.
This advertisement does not commit the Government to award a contract.
OPERATE CAENORHABDITIS GENETIC CENTER
RFP: NIH-RR-89-07
P.T. 34; K.W. 1002019, 1002027, 0780005
Division of Research Resources
The Division of Research Resources requires the operation of a caenorhabditis
genetic center to acquire, maintain, and distribute wild-type and mutant
strains of C. elegans for biomedical research and to characterize these
strains, stimulate research using C. elegans as a model system and to act as a
resource of genetic information for investigators. The Government anticipates
the award of one three-year cost reimbursement-type contract.
This is an announcement of an anticipated request for proposals which will be
issued on or about May 1, 1989. The closing date for receipt of proposals
will be on or about June 15, 1989.
The RFP will be available upon request from:
Danielle Kaczensky, Contracting Officer
Research Contracts Branch, DCG
National Institutes of Health
Building 31, Room 1B44
9000 Rockville Pike